Par Pharmaceutical Companies Inc
Par Pharmaceutical Companies — Investor Day (September 2007)
52 slides from Par Pharmaceutical Companies's investor day presentation, Sep 28, 2007

Slide 1: Par Pharmaceutical Analyst / Investor Day
Focus - Execution - Value Par Pharmaceutical Analyst / Investor Day September 28, 2007

Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this presentation contain information that is not historical, these statements are es

Slide 3: Today's Agenda
Today's Agenda Par's Strategy Operational Excellence Generic Business Branded Business Financial Update Looking Ahead

Slide 4: Par's Creed
Par's Creed WE ANSWER TO PATIENTS, to whom more than one million Par prescriptions are dispensed each week in the U.S. Therefore, we will assure our products are scientifically sound and of uncompromising quality. In a world with significant unmet medical needs, we will always remember that the pati

Slide 5: Par's Strategy
Par's Strategy Patrick G. LePore Chairman, CEO and President

Slide 6: Par at a Glance
Par at a Glance Develops, manufactures and markets generic drugs and innovative proprietary pharmaceuticals for specialty markets Generated $725 million in revenues in 2006 in two distinct divisions Generics 2006 revenues of $676 million 85 marketed product families 45 ANDAs Expanding pipeline Stron

Slide 7: Strong, Experienced Management Team
Strong, Experienced Management Team Patrick LePore President and CEO 30 years in pharma, including Cardinal Health, Boron LePore and Hoffmann-La Roche Jerry Martino EVP and COO 23 years in pharma and finance, including 12 at Schering-Plough Veronica Lubatkin EVP and CFO 22 years in pharma and financ

Slide 8: Key Accomplishments To Date
Key Accomplishments To Date Strengthened management structure Refocused R&D 8 potential first-to-files during the last 12 months Terminated non-core assets 9 generic launches during the last 12 months Megace ES sales annualizing at over $75 million In-licensed 3 supportive care branded products Stre

Slide 9: Refocusing Our Strategy
Refocusing Our Strategy Generics Focus on fewer, better products with higher barriers to entry Greater emphasis on internal product development First-to-files Leverage sales and marketing strength (AG opportunities) Focused on profitability Branded In-license late stage supportive care products Leve

Slide 10: Building Long-Term Value
Building Long-Term Value DIFFERENTIATING FACTORS People Operational Excellence Proven Execution Strategic Focus

Slide 11: Operational Excellence
Operational Excellence Gerard A. Martino Executive Vice President and COO

Slide 12: Taking Action to Drive Execution
Taking Action to Drive Execution Slice 9 East 16 16 16 16 PEOPLE Business Development R&D Supply Chain Financial Systems and Controls Continued strength in sales and marketing Experienced leadership team Refocused business development and R&D Enhanced processes and controls Working collaboratively

Slide 13: Generic Business Review
Generic Business Review Paul V. Campanelli Executive Vice President and President, Generics Division

Slide 14: Leading Generics Business
Leading Generics Business Leading mid-size U.S. manufacturer and distributor of generic pharmaceuticals Ranked 7th in U.S. by sales1 Generated record revenues of $676 million in 2006 Develops products internally and in partnership with other pharmaceutical companies Portfolio includes 85 marketed pr

Slide 15: Highly Regarded Generic Competitor
Highly Regarded Generic Competitor Successful track record of partnerships Leverage business development, licensing and legal expertise Strong reputation for sales & marketing Excellent track record for successful product launches Distributing to top U.S. retail chains, wholesalers, distributors, ma

Slide 16: Evolving U.S. Generics Trends
Evolving U.S. Generics Trends Increasing number of companies filing ANDAs Over 36 new companies filed ANDAs over the last 18 months Emergence of low-cost global generics companies into U.S. market Lower R&D and manufacturing costs Generic companies pursuing international M&A opportunities Lower cost

Slide 17: Addressing Market Dynamics
Addressing Market Dynamics Strategic product selection Focus on fewer, better products with higher barriers-to-entry High-profit, first-to-file and other opportunities R&D programs focused on winning target first-to-files Greater emphasis on internal product development Strategically select external

Slide 18: Strategy Yielding Wins
Strategy Yielding Wins 15 first-to-file opportunities 7 first-to-file opportunities submitted to USFDA in 2007 year-to-date Ratio of first-to-files/ANDAs has increased from 6% in 2005 to 70% in 2007 36 products currently in development Shift to internal development programs ANDAs from internal devel

Slide 19: Promising Pipeline
Promising Pipeline Generic Product / Trade Name Brand Sales (in millions) MAT 06/07 ANDA Filer ANDA Filed Status Diazepam rectal gel / Diastat(r) $74 Par (Barr to market) 09/03 Settlement pending Sumatriptan vials and kit / Imitrex(r) $213 Par (Spectrum) 10/04 Settlement reached / launch 2008 Alpraz

Slide 20: Recent Product Launches
Recent Product Launches Par Other Market Share 0.56 0.44 44% 56% 51% Metoprolol ER 25 mg tabs / Toprol XL(r) Propranolol ER / Inderal LA(r) Source: IMS Health (NPA September 14, 2007 Weekly TRx Generic Data) Par Other Market Share 0.57 0.43 43% 57% Metoprolol ER 100/200 mg tabs / Toprol XL(r) Par Ot

Slide 21: Well-Positioned to Successfully Execute Strategy
Well-Positioned to Successfully Execute Strategy Restructured and refocused R&D Continue to focus on bringing to market differentiated, hard to manufacture products Shift product mix to predominantly internal R&D Generate top tier growing profit margins and significant cash flows Strengthened positi

Slide 22: Branded Business Review
Branded Business Review John A. MacPhee Executive Vice President and President, Branded Products Division

Slide 23: Promising Branded Division
Promising Branded Division Branded Division launched in 2005 with approval of Megace ES Megace ES conceived & developed by Par Generics Division Branded Division today Strong commercial infrastructure Foundational product annualizing >$75M (Q2 07) in net sales and growing Three Phase III pipeline pr

Slide 24: Branded Strategy at Work in 2007
Branded Strategy at Work in 2007 Established Megace ES as foundational product Focused our internal development program Leveraged commercial infrastructure Built pipeline Generated ~$19M in Q2 07 net sales; RXs continue to grow Divested PAR-101 and reduced R&D infrastructure Co-promotion of AndroGel

Slide 25: Introducing Strativa Pharmaceuticals
Building a high-growth proprietary pharmaceutical business Initial therapeutic focus: Supportive care (Oncology & HIV) and select oncologicals Commercial excellence: Sales and marketing expertise, management and execution Fully-deployed commercial infrastructure 3rd party payer / reimbursement exper

Slide 26: Significant Commercial Capabilities
Significant Commercial Capabilities President, Branded Products Division Senior VP, Sales & Marketing 2 Area Directors and 9 Regional Business Directors Senior Director, Managed Markets 92 person specialty sales force 17 person long-term care sales force 10 person managed markets group 12 marketing,

Slide 27: Why Supportive Care?
Why Supportive Care? Shift in trajectory Patients are living longer with HIV / AIDS / Cancer Increasing complications From living with disease and from treatments for the disease Patients and healthcare providers have unique needs Better served by focused and dedicated specialty pharmaceutical compa

Slide 28: HIV/Oncology: Concentrated Markets
HIV/Oncology: Concentrated Markets 10 9 8 7 6 5 4 3 HIV Prescribers 71 129 180 243 324 448 652 1071 10 9 8 7 6 5 4 3 Oncologists 343 562 761 964 1241 1578 1506 1258 11,000 physicians represent 80% of prescription market * Market defined by IMS as misc anti-neoplastics

Slide 29: HIV/Oncology Supportive Care: Key Customers
HIV/Oncology Supportive Care: Key Customers Treaters 3,000 AIDS Specialists 8,000 Oncologists 12,000 Select Internists 2,000 Pain Specialists 25,000 MDs Influencers Oncology Nurses Dieticians Advocacy Groups Specialty Pharmacies Payers/Customers Commercial Plans Part D Plans Medicaid ADAP Oncology G

Slide 30: Strativa: An Attractive Partner
Strativa: An Attractive Partner Specialty products focus and expertise Proven success (Megace ES) Full sales and marketing support, including reimbursement Therapeutic expertise and know-how Medical affairs and regulatory support Specialty company focus backed by Par Pharmaceutical's resources Acces

Slide 31: Accelerated Business Development
Accelerated Business Development Dedicated business development resources Focused product targeting strategy Proprietary, single source, U.S.-focused RXs Currently marketed or late-stage development Fulfill unmet medical needs / unique selling proposition Not large enough to meet critical mass requi

Slide 32: Rigorous Due Diligence Process
Rigorous Due Diligence Process Initial Commercial Assessment (Secondary market data, literature review, Dx & Tx patterns, etc.) Patient and prescription-based models to predict commercial potential Refine model through primary research with thought leaders and physicians DUE DILIGENCE Medical Clinic

Slide 33: Late Stage Branded Portfolio
Late Stage Branded Portfolio Late Stage Investments in Pipeline Accelerates Branded Strategy Product Indication Phase I Phase II Phase III Target NDA Filing Approved Loramyc(tm) Zensana(tm) AndroGel(r) * Megace(r) ES CINV & PONV Oral Candidiasis Testosterone Replacement Therapy Anorexia, Cachexia, o

Slide 34: Megace ES: Excellent Foundation Product
Megace ES: Excellent Foundation Product Improved formulation of megestrol acetate oral suspension utilizing NanoCrystal(r) Technology (Elan) Approved July 2005 via 505(b)(2) regulatory pathway Indicated for anorexia, cachexia, or unexplained weight loss in AIDS patients Primary focus on conversion o

Slide 35: Megace ES: Offering Multiple Benefits
Megace ES* 625mg/5 mL Megace 800mg/20mL Fasting 1041 187 Megace ES: Offering Multiple Benefits Megace ES offers: Bioavailability for unfed patients 1 teaspoon vs. 4 teaspoons QD dosing Less viscous Mean Cmax (ng/mL) Bioavailability in Fasted-State * Extrapolated from 2 single-center bioavailability

Slide 36: Megace ES: TRx Actuals
+32% +10% Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 LE Q4 JULY LE MES TRXs 4250 13108 19869 28460 37612 41224 44160 49098 54255 58438 Megace ES: TRx Actuals % growth vs. prior qtr ~$19M Q2 net sales +11% +7% +51% +308% +43% Source: IMS Health

Slide 37: Loramyc (miconazole Lauriad) Overview
Loramyc (miconazole Lauriad) Overview Miconazole buccal tablet (Lauriad) in development for oropharyngeal candidiasis (OPC) U.S. commercialization rights from Bioalliance with right to advise on development program $15M upon execution, $20M FDA approval milestone, royalties and sales milestones Canc

Slide 38: Zensana (ondansetron) Overview
Zensana (ondansetron) Overview Unique, oral spray formulation of ondansetron in development for CINV, RINV, PONV Acquired North American commercial rights from Hana Biosciences; Entered collaboration agreement with Novadel to reformulate Zensana $5M equity investment in Hana, milestone payments and

Slide 39: Pafuramidine Overview
Pafuramidine Overview Novel antimicrobial agent in Phase III development for pneumocystis pneumonia in AIDS patients U.S. commercialization rights from Immtech for PCP with right to advise on development program $3M upon execution, $29M in potential development milestones, royalties and potential sa

Slide 40: Well-Positioned to Achieve Long-Term Goals
Well-Positioned to Achieve Long-Term Goals Develop Branded Division identity Drive Megace ES sales growth and profitability Successfully commercialize pipeline Accelerate growth through in- licensing Launch Strativa Pharmaceuticals Excellence in sales and marketing execution Invest in additional lat

Slide 41: Financial Update
Financial Update Gerard A. Martino Executive Vice President and COO

Slide 42: Progress on Financial Reporting
Progress on Financial Reporting Key Financial Milestones Dates 2005 10-K/A filed March 13, 2007 10-Q/As for first and second quarters of 2006 filed July 10, 2007 10-Q/A for third quarter of 2006 filed July 30, 2007 10-K for 2006 September 6, 2007 Form 10-Q for first and second quarters of 2007 Earli

Slide 43: Estimated Operating Results For Months Ended 06/30/07
Estimated Operating Results For 6 Months Ended 06/30/07 RANGE (in millions except per share amounts) ONE-TIME ITEMS Revenues $390 - $395 Gross Margin $140 - $143 R&D $28 $(3) Pafuramidine SG&A $65 $(2) Severance Other Income, Net $15 $21 PAR 101 $(6) High Yield Inv Loss Pre-tax Income $62 - $65 Net

Slide 44: Estimated Sales Highlights For Months Ended 06/30/07
Estimated Sales Highlights For 6 Months Ended 06/30/07 PRODUCT SALES (in millions) Fluticasone $95 Propanolol 42 Megace ES 36 Metropolol 30 Amoxicillin 25 Cabergoline 18 Other Product Related Revenues: Androgel co-promotion 5 Ondansetron Royalties 8

Slide 45: Estimated Operating Results For Full Year 2007
Estimated Operating Results For Full Year 2007 Expected Second Half Impacts: Competition on Product Sales: Fluticasone Propanolol Cabergoline Ondansetron Royalties Revenues $730 - $765 million

Slide 46: Estimated Operating Results For Full Year 2007
Estimated Operating Results For Full Year 2007 IMPACT OF ONE-TIME ITEMS (in millions, except per share amounts) FY 2007 Severance $2 Branded Milestone Payments 19 High Yield Investment Loss 6 PAR 101 (21) Total One-Time Items $6 EPS Impact (fully diluted) $0.10 EPS (fully diluted) adjusted for one-t

Slide 47: Strong Balance Sheet
Strong Balance Sheet (in millions) 06/30/07 12/31/06 CURRENT ASSETS: Cash, equivalents and available for sale securities $342 $213 Accounts receivable, net 37 95 Inventories 86 106 Total current assets: $564 $514 Total non-current assets: $263 $296 CURRENT LIABILITIES: Short-term and current portion

Slide 48: Stock Repurchase Program
Stock Repurchase Program Strong balance sheet position Confidence in company's strategy and long-term outlook Board approved $75 million stock repurchase program 10% of outstanding shares at today's price

Slide 49: The "New" Par Pharmaceutical
The "New" Par Pharmaceutical Refocused strategy Proven successful execution Leading mid-size Generics business Growing Branded business with strong product pipeline Sustainable business processes in place to drive long-term growth and profitability Leading to Greater Transparency for Investors

Slide 50: Milestones to Continued Success
Milestones to Continued Success 6 - 10 first-to-files per year >50% of products to come from internal development Increase gross margins Continue AG opportunities Accelerate brand growth Additional in-licensed products Continue growth in Megace ES >$250 million in annualized sales GENERIC BUSINESS B

Slide 51: Question & Answer Session
Question & Answer Session

Slide 52: Par Pharmaceutical Analyst / Investor Day
Par Pharmaceutical Analyst / Investor Day September 28, 2007 Focus - Execution - Value
Source: SEC EDGAR · 8-K filed Sep 28, 2007



